The disclosure relates to a composition comprising buprenorphine and a &mu opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.75 and about 2.2. The composition may comprise an antagonist of formula I. The composition may be used to treat a depressive disorder.